JPWO2020213344A1 - - Google Patents

Info

Publication number
JPWO2020213344A1
JPWO2020213344A1 JP2021514840A JP2021514840A JPWO2020213344A1 JP WO2020213344 A1 JPWO2020213344 A1 JP WO2020213344A1 JP 2021514840 A JP2021514840 A JP 2021514840A JP 2021514840 A JP2021514840 A JP 2021514840A JP WO2020213344 A1 JPWO2020213344 A1 JP WO2020213344A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514840A
Other versions
JP7423083B2 (ja
JPWO2020213344A5 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020213344A1 publication Critical patent/JPWO2020213344A1/ja
Publication of JPWO2020213344A5 publication Critical patent/JPWO2020213344A5/ja
Application granted granted Critical
Publication of JP7423083B2 publication Critical patent/JP7423083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021514840A 2019-04-18 2020-03-19 大腸癌の発癌リスクを検出する方法及びキット Active JP7423083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019079535 2019-04-18
JP2019079535 2019-04-18
PCT/JP2020/012468 WO2020213344A1 (ja) 2019-04-18 2020-03-19 大腸癌の発癌リスクを検出する方法及びキット

Publications (3)

Publication Number Publication Date
JPWO2020213344A1 true JPWO2020213344A1 (ja) 2020-10-22
JPWO2020213344A5 JPWO2020213344A5 (ja) 2023-03-28
JP7423083B2 JP7423083B2 (ja) 2024-01-29

Family

ID=72837241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514840A Active JP7423083B2 (ja) 2019-04-18 2020-03-19 大腸癌の発癌リスクを検出する方法及びキット

Country Status (5)

Country Link
US (1) US20220195534A1 (ja)
EP (1) EP3957732A4 (ja)
JP (1) JP7423083B2 (ja)
CN (1) CN113710800A (ja)
WO (1) WO2020213344A1 (ja)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
JP2011033495A (ja) * 2009-08-03 2011-02-17 Koto Biseibutsu Kenkyusho:Kk 予後予測のための大腸癌組織の検査方法
US20190078092A1 (en) * 2014-07-30 2019-03-14 The Administrators Of The Tulane Educational Fund Preventing tumor development and metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148668A1 (ja) 2010-05-25 2011-12-01 株式会社 島津製作所 大腸がんマーカーガレクチン、採血試料中のガレクチン濃度の分析方法及び大腸がんマーカーガレクチン検出キット
CN105755152A (zh) * 2016-05-09 2016-07-13 厦门稀土材料研究所 Jam3基因在制备结直肠癌诊断试剂盒中的应用及试剂盒
US10711312B2 (en) * 2016-07-12 2020-07-14 The Regents Of The University Of California Methods for immunotherapy-based treatment and assessment of cancer
CN107385091B (zh) * 2017-09-07 2021-02-12 暨南大学 Cdc42bpa作为结直肠癌转移诊断与预测预后的生物标志物
KR20190044878A (ko) 2017-10-23 2019-05-02 삼성전자주식회사 뉴럴 네트워크에서 파라미터를 처리하는 방법 및 장치

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
JP2011033495A (ja) * 2009-08-03 2011-02-17 Koto Biseibutsu Kenkyusho:Kk 予後予測のための大腸癌組織の検査方法
US20190078092A1 (en) * 2014-07-30 2019-03-14 The Administrators Of The Tulane Educational Fund Preventing tumor development and metastasis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALMEIDA DE OLIVEIRA ET AL.: "Inducible Nitric Oxide Synthase in the Carcinogenesis of Gastrointestinal Cancers", ANTIOXIDANTS & REDOX SIGNALING, vol. 26, no. 18, JPN6020018598, 18 November 2017 (2017-11-18), pages 1059 - 1077, XP055751277, ISSN: 0005144760, DOI: 10.1089/ars.2016.6850 *
AMATYA N. ET AL.: "IL-17 Signaling: The Yin and the Yang", TRENDS IMMUNOL, vol. 38, JPN6023022707, 2017, pages 310 - 322, ISSN: 0005144766 *
ESTEBAN-JURADO C. ET AL.: "Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial", GENET MED, vol. 17, JPN6023022704, 2015, pages 131 - 42, XP093005629, ISSN: 0005144763, DOI: 10.1038/gim.2014.89 *
HAO XP. ET AL.: "Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and co", CANCER RES, vol. 61, JPN6023022702, 2001, pages 419 - 22, ISSN: 0005144761 *
NANKI K. ET AL.: "Somatic inflammatory gene mutations in human ulcerative colitis epithelium", NATURE, vol. 577, JPN6023022706, 18 December 2019 (2019-12-18), pages 254 - 259, XP036981827, ISSN: 0005144765, DOI: 10.1038/s41586-019-1844-5 *
TRAICOFF JL. ET AL.: "Templeton DJ, Casey G, Kaetzel CS. Characterization of the human polymeric immunoglobulin receptor (", J BIOMED SCI, vol. 10, JPN6023022703, 2003, pages 792 - 804, ISSN: 0005144762 *
YAN ET AL.: "IL-17R deletion predicts high-grade colorectal cancer and poor clinical outcomes", INT. J. CANCER, vol. 145, JPN6020018597, 10 January 2019 (2019-01-10), pages 548 - 558, ISSN: 0005144759 *
鈴木 貴夫: "大腸がんの発生メカニズムの解明と分子標的治療薬の臨床応用", 仙台医療センター医学雑誌, vol. 5, JPN6023022705, 2015, pages 13 - 21, ISSN: 0005144764 *

Also Published As

Publication number Publication date
WO2020213344A1 (ja) 2020-10-22
EP3957732A4 (en) 2023-01-18
EP3957732A1 (en) 2022-02-23
CN113710800A (zh) 2021-11-26
JP7423083B2 (ja) 2024-01-29
US20220195534A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
BR112019017762A2 (ja)
BR112021017339A2 (ja)
BR112019016141A2 (ja)
BR112021017939A2 (ja)
BR112021017738A2 (ja)
BR112021017892A2 (ja)
BR112021017782A2 (ja)
AU2020104490A5 (ja)
BR112021017637A2 (ja)
BR112021008711A2 (ja)
BR112019016142A2 (ja)
BR112019016138A2 (ja)
BR112021017728A2 (ja)
BR112021017355A2 (ja)
BR112021017703A2 (ja)
BR112021018584A2 (ja)
BR112021015080A2 (ja)
BR112021012348A2 (ja)
BR112021018084A2 (ja)
BR112021013944A2 (ja)
BR112021013128A2 (ja)
BR112021018484A2 (ja)
BR112021016821A2 (ja)
BR112021017732A2 (ja)
BR112021017949A2 (ja)

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230316

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240110

R150 Certificate of patent or registration of utility model

Ref document number: 7423083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150